No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 5 of the 31 quarters in the window, leaving 26 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S 1.0x · 10Y median 1.8x · 39th percentile · as of Oct 5, 2026
Annualized revenue (TTM) · by quarter, last 32
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2026-10-05. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FMP quote market capitalization / four-quarter operating cash flow less absolute capital expenditures. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Unrounded diluted TTM EPS / FMP quote price × 100. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2022-11-07.
Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter operating cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
Four-quarter free cash flow / FMP quote market capitalization × 100. Quote observation: 2026-10-06T11:55:54.874Z. Latest historical point 2023-11-20. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
The latest delayed quote for BioNexus Gene Lab Corp. (BGLC) stock was $1.28 as of Oct 5, 2026, 4:00 PM EDT, up 0.79% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -75.6% · 3-year avg -43.8%/yr · 5-year avg -61.0%/yr
BioNexus Gene Lab Corp. (BGLC), established in 2017 and headquartered in Kuala Lumpur, Malaysia, conducts business through two primary subsidiaries.
Industrial - Distribution · Kuala Lumpur, WP
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
N/A
EPS Estimate
N/A
Revenue Est.
N/A
Last Quarter Results
EPS
$-0.12
vs Estimate
N/A
Revenue
$76156.00
vs Estimate
N/A
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BGLC | $3.09M | $1.28 | +0.79% | -75.64% | -61.00% | N/A | N/A |
| 2DFSC | $2.69M | $1.01 | -9.01% | -72.82% | -86.24% | N/A | vs BGLC |
| 3ATXG | $3.51M | $3.40 | +3.66% | -78.46% | -68.67% | N/A | vs BGLC |
| 4DPU | $2.64M | $1.41 | -9.10% | -56.84% | N/A | N/A | vs BGLC |
| 5BIYA | $3.78M | $1.40 | -12.50% | -99.02% | N/A | N/A | vs BGLC |
| 6DETX | $4.18M | $2.05 | -2.84% | N/A | N/A | N/A | vs BGLC |
forward FY estimate
N/A
Consensus Rating
No analyst recommendations available
Average Price Target
N/A
Low
N/A
Current
$1.28
High
N/A
